Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment

Bo Fan1†, Alradhi Mohammed1†, Yuanbin Huang1†, Hong Luo2, Hongxian Zhang1, Shenghua Tao1, Weijiao Xu2, Qian Liu3, Tao He1, Huidan Jin4, Mengfan Sun5, Man Sun2, Zhifei Yun3, Rui Zhao5, Guoyu Wu6* and Xiancheng Li1*

1 Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, China, 2 Clinical Medicine, Dalian Medical University, Dalian, China, 3 Medical Imaging, Dalian Medical University, Dalian, China, 4 Department of Anaesthesiology, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China, 5 Department of Pharmacy, Zhongshan College of Dalian Medical University, Dalian, China, 6 Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China

Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.

Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa (P=0.175). Stratified analyses of sex showed that aspirin intake did not lead to a lower risk of BCa in female patients (P=0.063). However, the male population who regularly took aspirin had a lower incidence of BCa (OR=0.748, 95% CI=0.584-0.958, P=0.021). Subgroup analyses stratified by smoking found a significant reduction in the risk of BCa in current smokers with aspirin intake (OR=0.522, 95% CI=0.342-0.797, P=0.002). In terms of prognosis of BCa, patients with a history of aspirin intake did not have a markedly longer OS or RFS than those with no history of aspirin intake by Kaplan-Meier curves. Stratified analysis by sex showed no correlation between aspirin intake and the recurrence or survival of BCa for either male or female patients. However, in people younger than 68, aspirin intake seemed to have prolonged effects for overall survival (HR=3.876; 95% CI=1.326-11.325, P=0.019). Then, we performed a meta-analysis and the combined results from 19 articles and our study involving more than 39524 BCa cases...
indicated that aspirin intake was not associated with the occurrence of BCa ($P=0.671$). Subgroup analysis by whether regular use of aspirin, by the mean duration of use of aspirin, by sex, by smoking exposure, by research region and by study type also supported the above results. In terms of the impact of aspirin intake on the prognosis of patients with BCa, 11 articles and our study involving 8825 BCa cases were eligible. The combined results showed that patients with aspirin intake did not have significantly influence on survival, recurrence, progression and metastasis than those without aspirin intake. On the whole, both our retrospective study and literature meta-analysis suggested a lack of a strong relevant association between the use of aspirin and the incidence or prognosis of BCa. Thus, additional long-term follow-up prospective research is warranted to clarify the association of aspirin with BCa incidence and prognosis.

**Keywords:** urinary bladder neoplasms, aspirin, risk, prognosis, case-control, meta-analysis

**BACKGROUND**

Bladder cancer (BCa) is the 11th most common cancer in the world. The global age-standardized incidence rate per 100,000 persons/year is 2.2 for women and 9.0 for men (1, 2). According to the National Cancer Institute, the estimated numbers of new BCa cases and deaths in the USA alone (2014) will be 74,690 and 15,580, respectively (3, 4). In China, the incidence and mortality rates have increased gradually in the past few years. According to the National Central Cancer Registry (NCCR) of China 2015 annual report, the overall incidence of BCa was 7.68/10^5 (5, 6). Among patients with superficial or non-muscle invasive tumors after transurethral resection or perfusion therapy, 70% would experience recurrence, and 10% to 20% would show progression to muscle-invasive tumors (7, 8). Due to the unfavorable prognosis of muscle-invasive cancer, the treatment involves multiple modalities, including radical surgery, radiotherapy, and chemotherapy. However, nearly half of these patients develop metastases and die within 3 years (7, 9). The occurrence or recurrence of BCa is a molecular biological change or process that is effected by occupational factors, non-occupational factors, and genomics and proteomics factors (10). Other non-occupational factors, including cigarette smoking (11), drinking water used for washing or cleaning drinking water used for washing or cleaning (12) the consumption of substances with nitrate and nitrite content (13), alcohol consumption (14), and special drug intake (15, 16), have also been associated with BCa but are less well established. Therefore, early detection strategies and prognosis monitoring are essential for reducing mortality from BCa.

Aspirin, a typical non-steroidal anti-inflammatory drug, has been widely used for pain, fever and cardiovascular disease (17, 18). In recent years, a large accounts of studies have suggested that aspirin has a potential preventive effect in several types of cancers (18–20). The antitumor activity of aspirin is thought to be based mainly on two different mechanisms. First, aspirin may interfere with carcinogenesis by inhibiting the target of cyclooxygenase (COX), which is produced in response to inflammation and leads to angiogenesis and reduced apoptosis. As one of isoforms of cyclooxygenase, the level of COX-2 may not only increase the malignant properties of BCa cells but also be related to high-grade and advanced-stage BCa patients (21, 22). Second, aspirin plays roles in promoting apoptosis or inhibiting the proliferation of tumor cells by interfering with the pathway independent of COX-2 as an anticancer agent. Aspirin inhibits the growth of PI3K mutant breast cancer by activating AMP-activated protein kinase (AMPK) and inhibiting mechanistic target of rapamycin complex 1 (mTORC1) signaling independent of COX-2 and IKK-β/NF-κB (23). Furthermore, aspirin inhibited the proliferation of neuroblastoma cells, upregulated p21Waf1 and regulated Rb1 to promote differentiation through a Cox-independent mechanism (24).

Since aspirin has apparent preventive effects on other tumors, its role in BCa has also received attention. The findings of the impact of aspirin intake and the incidence and mortality of BCa have been inconclusive. Moreover, few studies on the relationship between aspirin intake and BCa in mainland China, especially in Northeast China. To explore whether the use of aspirin is associated with altered risk of BCa, we conducted a case-control study by enrolling 1121 patients with BCa. To avoid bias from single-center study results, we further completed a meta-analysis of eligible literature by searching electronic journals or databases for documents before March 1, 2021. The connection between aspirin intake and the incidence and prognosis of BCa was investigated, which helps to further determine whether the use of aspirin has a preventive effect on BCa. Our analysis provides a basis for further exploration of the role of aspirin in the future.

**MATERIALS AND METHODS**

**Retrospective Study**

**Study Population for Exploring the Association of Aspirin Intake and Risk of Bladder Cancer**

This study was approved by the institutional review committee of the Second Affiliated Hospital of Dalian Medical University. The study population consisted of 1121 bladder cancer cases with...
average age 68 years old, ranging from 49 to 84 years. The control group comprised of 2242 individuals without a bladder cancer diagnosis during the study period, which were hospitalized in the department of respiratory, gastroenterology, orthopedic surgery, dermatology, and cardiology, etc.

Patients in both groups underwent 1:2 matching based on sex, age, and follow-up period at the index date of each case. The possible risk factors for the occurrence of BCa, including age, marital status, smoking status, alcohol use, aspirin use, metformin use, history of cardiovascular disease, history of cerebrovascular disease and history of diabetes were extracted from clinical history information.

Study Population for Exploring Association of Aspirin Intake and Prognosis of Bladder Cancer
1121 patients in the case group who were pathologically diagnosed with bladder cancer by pathological biopsy or surgical biopsy at the Second Affiliated Hospital of Dalian Medical University were included in the study. The clinical and pathological baseline data, including age, gender, histological grading, T stage, lymph node metastasis, distant metastasis, type of surgery were recorded. TMN staging and histological grading were determined according to the 2004 WHO/ISUP classification. Recurrence of bladder cancer is defined as visual and/or biopsy evidence of a tumor confirmed by cystoscopy or urine cytology.

Assessment of Aspirin Use
Aspirin users were defined as those who used at least 81mg aspirin daily at least twice a week for 1 month or more. Nonusers are subjects who had never used the drug or had used it for <1 month. The average daily dose of aspirin for each aspirin user was also obtained by dividing the cumulative dose of aspirin by the cumulative number of days of aspirin use. The indication for the use of aspirin (i.e., analgesic or cardiovascular disease, cerebrovascular disease prevention) was also recorded (25–27). Patients were stratified according to aspirin intake for most (50% or more) of the interval between diagnosis and the date of the first tumor recurrence or last follow-up. The exclusion criteria were as follows: (1) Unable to obtain accurate medication records, demographic data, or patient characteristics. (2) Identification of a history of exposure to carcinogens. (3) Patients on clopidogrel, warfarin, or statins alone or in combination with other fibrin clotting inhibitors. (4) Aspirin use was contraindicated.

Statistical Analysis
SPSS version 13.0 (SPSS Inc., Chicago, USA) was used for analysis. The associations between aspirin intake and clinicopathological parameters were evaluated by the chi-square test. Continuous data and frequency data were analyzed by t test and Fisher’s exact test. When the independent variables were screened in order to investigate the risk factors for the occurrence of BCa, adjusted odds ratios (ORs) or relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were calculated by univariate and multivariate logistic regression analysis. By univariate analysis, those with a significant P value less than 0.05 in this test were included in the multivariate regression analysis. To evaluate the overall survival (OS) which was the interval from surgery to death and recurrence-free survival (RFS) which was the interval from surgery to intravesical recurrence in patients with BCa, the Kaplan-Meier curve and log-rank test were used. After assessing clinicopathologic factors by univariate Cox regression model, statistically significant variables were put into multivariate Cox regression analysis to find independent prognostic factors for OS and RFS. After SPSS analysis, the P value of the above parameters was obtained. A P-value less than 0.05 was considered statistically significant.

Meta-Analysis
Search Strategy
The implementation of this meta-analysis was conducted based on the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines. The PRISMA checklist was shown in Table 1. Our meta-analysis has been already registered of the review protocol on PROSPERO (CRD42021245411). The study retrieved articles from the PubMed, Embase, Ovid Medicine, Cochrane Library and Scopus databases published before May 1, 2021, to identify relevant studies evaluating aspirin intake and its effects on the occurrence and prognosis of BCa using the following medical subject headings that include all spelling variations: “bladder cancer” and “aspirin”, “occurrence”, “risk” and “prognosis”, “survival” and “recurrence”. Without national and linguistic restrictions, after reviewing the duplicate data, the two reviewers independently screened the titles and abstracts, excluding articles that were not associated with our research, reviews, and related animal experiments and maximizing data quality.

Selection Criteria
Studies satisfying the following criteria were included in our analysis: (1) the histologic type of the tumors was urothelial carcinoma of the bladder by histologic or pathologic examination; (2) the association between aspirin intake and the risk of BCa or prognosis of patients with BCa was investigated; and (3) sufficiency of data for the calculations of OR/RR/hazard ratio (HR), 95% CI and P-value. Accordingly, the following exclusion criteria were applied: (1) studies in the form of reviews, letters to the editor, commentaries, or case reports that lacked original data; (2) molecular biology research that explored the impact of aspirin on cancer cell lines and animal models; and (3) studies in which the HR/OR/RR and its standard error could not be collected based on the given information.

Data Extraction
After the full-text evaluation, the two authors extracted the data separately for further qualitative and quantitative analysis to increase the authenticity of the data. For the selected articles, we extracted data from each study, including the first author, publication time, region, type of study, study period the number of participants and BCa cases, age, the usage of aspirin, HR/OR/RR, and adjustment factors.
**TABLE 1 | PRISMA checklist.**

| Section/topic                  | #  | Checklist item                                                                 | Reported on page # |
|-------------------------------|----|---------------------------------------------------------------------------------|--------------------|
| **TITLE**                     | 1  | Identify the report as a systematic review, meta-analysis, or both.              | 1                  |
| **ABSTRACT**                  | 2  | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1-2                |
| **INTRODUCTION**              | 3  | Describe the rationale for the review in the context of what is already known.   | 2                  |
| **METHODS**                   | 4  | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 2                  |
| Protocol and registration     | 5  | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 3                  |
| Eligibility criteria          | 6  | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 3                  |
| Information sources           | 7  | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 3                  |
| Search                        | 8  | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 3                  |
| Study selection               | 9  | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 3                  |
| Data collection process       | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 3                  |
| Data items                    | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 3                  |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 5: Figure 1        |
| Summary measures              | 13 | State the principal summary measures (e.g., risk ratio, difference in means).    | 5                  |
| Synthesis of results          | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis. | 5                  |
| Risk of bias across studies   | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5                  |
| Additional analyses           | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 5                  |
| **RESULTS**                   | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 8: Figure 2        |
| Study characteristics         | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 8, 9: Tables 7–9   |
| Risk of bias within studies   | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 5: Figure 1        |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 9, 10, 12–17: Figures 3, 5–13 |
| Synthesis of results          | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 9, 10, 12–17: Figures 3, 5–13 |
| Risk of bias across studies   | 22 | Present results of any assessment of risk of bias across studies (see item 15). | 9, 10, 12–17: Figures 3, 5–13 |
| Additional analysis           | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]). | 9, 10, 12–17: Figure 4 |
| **DISCUSSION**                | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 18, 19             |
| Summary of evidence           | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 19                  |
| Limitations                   | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 19                  |
| **FUNDING**                   | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 20                  |
Quality Assessment
The quality assessment used the most recent version of the risk of bias tool recommended in the ROBINS-I checklist (28) for systematic reviews of interventions for the included studies. Our selected studies were assessed for bias due to confounding, selection bias, intervention measurement, missing data bias, outcome measurement, reporting bias, and other types of bias. As shown in Figure 1, the risk of bias of our meta-analyses measured by ROBINS-I framework for individual studies was generally low to moderate.

Sensitivity Analysis
Whether influential studies needed to be secondary for exclusion from our meta-analysis was determined by sensitivity analysis. The robustness of the pooled estimates with respect to the employed individual investigations was evaluated using the leave-one-out method based on the Q-test. Lower heterogeneity was determined after eliminating the indicated studies if the $P_Q$ value > 0.05. Conversely, low heterogeneity was calculated by removing a single study, indicating that the selected studies did not contribute to the heterogeneity of the overall meta-analysis.

Statistical Analysis
The Stata 12.0 statistical software package (Stata Corp, College Station, TX, USA) was used for all data analyses. We calculated the OR/RR/HR with a 95% CI. The Q-test was used to assess the statistical heterogeneity and judge the $p$-value qualitatively. The $I^2$ value in the $I^2$ test describes the proportion of the total variation due to heterogeneity rather than sampling errors, and $I^2 > 50\%$ or $P<0.05$ indicates a high degree of heterogeneity. The random-effects model was used; otherwise, there was no heterogeneity, and the fixed-effects model was used. The potential bias was assessed by a funnel plot and Egger’s test, and when the funnel plot was symmetrically distributed, there was no significant bias. Conversely, if the funnel plot exhibits skewness and asymmetry, this indicated bias.

---

**FIGURE 1** Methodological quality graph for meta-analysis of the incidence (A), outcomes of surgery (B) and prognosis (C) of bladder cancer. The review authors’ judgements about each methodological quality item of ROBINS-I presented as different colors across all included studies. The red, yellow and green colors represent critical, moderate and low bias, respectively.
RESULTS
Retrospective Study to Explore the Association of Aspirin Intake and Risk of Bladder Cancer

Baseline Characteristics

The clinical characteristics of the 1121 cases and 2242 controls are shown in Table 2. The following variable information was selected as the prognostic factors in our study: age at diagnosis <68 or >68, marital status, smoking status (nonsmoker, current smoker, former smoker), alcohol use (nondrinker, current drinker, former drinker), history of aspirin intake (yes, no), history of metformin use (yes, no), history of cardiovascular disease (yes, no), history of cerebrovascular disease (yes, no), and history of diabetes (yes, no). In the multivariate logistic regression analysis, we found that gender (OR=1.263; 95% CI=1.026-1.556; P=0.028); marital status (OR=0.165; 95% CI=0.940-0.289; P<0.001); current smoking status (OR=2.360; 95% CI=1.936-2.875; P<0.001); current alcohol use (OR=0.615; 95% CI=0.496-0.762; P<0.001); former alcohol use (OR=0.314; 95% CI=0.188-0.525; P<0.001) and history of cardiovascular disease (OR=0.212; 95% CI=0.162-0.276; P<0.001) were associated with a strong risk of BCa.

The Association of Aspirin Intake and Risk of Bladder Cancer

Among the controls and the cases identified as BCa, the patients who used aspirin accounted for 10.1% of the total number of patients with BCa and 11.6% of the control group. As shown in Table 3, The analysis showed that the regular use of aspirin was not associated with a reduced incidence of BCa (OR=0.851, 95% CI=0.674-1.075, P=0.175). Subgroup analyses stratified by sex showed no correlation between aspirin intake and the risk of BCa in female patients (OR=2.000, 95% CI=0.950-4.190, P=0.063). However, the male population who regularly took aspirin had a lower incidence of BCa (OR=0.748, 95% CI=0.584-0.958, P=0.021). Moreover, subgroup analyses stratified by smoking status showed no reduction in the risk of BCa for nonsmokers (OR=1.200, 95% CI=0.879-1.630, P=0.252) or former smokers (OR=0.913, 95% CI=0.437-1.900, P=0.807) who used aspirin daily. In contrast, our results found a significant reduction in the risk of BCa in current smokers with aspirin intake (OR=0.522, 95% CI=0.342-0.797, P=0.002). In addition, subgroup analyses stratified by drinking status showed no change in the risk of BCa for nondrinkers (OR=0.970, 95% CI=0.744-1.260, P=0.822), current drinkers (OR=0.651, 95% CI=0.377-1.120, P=0.121), or former drinkers (OR=0.227, 95% CI=0.029-1.780, P=0.126) who used aspirin daily.

### Table 2 | Demographic characteristics of bladder cancer cases and controls.

|                          | Case group (n = 1121) | Control group (n = 2242) | Total | P value |
|--------------------------|-----------------------|----------------------------|-------|---------|
| Gender                   |                       |                            |       | 0.002   |
| Female                   | 193                   | 487                        | 680   |         |
| Male                     | 928                   | 1755                       | 2683  |         |
| Aspirin use              |                       |                            |       | 0.181   |
| No                       | 1008                  | 1981                       | 2989  |         |
| Yes                      | 113                   | 261                        | 374   |         |
| Age, years               |                       |                            |       | 0.661   |
| <68                      | 562                   | 1142                       | 1704  |         |
| ≥ 68                     | 559                   | 1100                       | 1659  |         |
| Marriage                 |                       |                            |       | <0.001  |
| No                       | 55                    | 19                         | 74    |         |
| Yes                      | 1066                  | 2223                       | 3289  |         |
| Smoking                  |                       |                            |       | <0.001  |
| Non-smoker               | 609                   | 1390                       | 1999  |         |
| Current smoker           | 449                   | 531                        | 980   |         |
| Former smoker            | 63                    | 321                        | 384   |         |
| Alcohol use              |                       |                            |       | <0.001  |
| Non-drinker              | 861                   | 1631                       | 2492  |         |
| Current drinker          | 239                   | 478                        | 717   |         |
| Former drinker           | 21                    | 133                        | 154   |         |
| History of cardiovascular disease |           |                            |       | 0.002   |
| No                       | 1025                  | 1970                       | 2995  |         |
| Yes                      | 98                    | 272                        | 368   |         |
| History of diabetes      |                       |                            |       | <0.001  |
| No                       | 928                   | 1736                       | 2664  |         |
| Yes                      | 193                   | 506                        | 699   |         |
| History of cerebrovascular disease |             |                            |       | <0.001  |
| No                       | 1049                  | 1661                       | 2710  |         |
| Yes                      | 72                    | 581                        | 653   |         |
| Metformin use            |                       |                            |       | 0.177   |
| No                       | 1067                  | 2108                       | 3175  |         |
| Yes                      | 54                    | 134                        | 188   |         |

The bold values were applied to highlight P-values which had statistically significance (i.e. P<0.05).
Retrospective Study to Explore the Association of Aspirin Intake and Prognosis of Bladder Cancer

A total of 1121 patients with newly developed BCa from Northeast China, mainland China, were identified from 2002 to January 2019 and divided into aspirin and non-aspirin groups.

Of these patients in Table 4, the male to female ratio was 928:193, and there were 559 patients aged 68 or greater. A total of 344 patients (30.7%) had pathologic stage T2-T4 disease, and 687 patients (61.3%) had high-grade disease (G2 to G3). Positive lymph nodes were present in 62 patients (5.3%), and distant metastasis was present in 33 patients (2.9%). All patients had a definite type of surgery; 854 underwent TURBT (76.2%), 58 underwent partial resection (5.2%), and 209

| TABLE 3 | Univariate and multivariate logistic regression analysis of risk factors for bladder cancer. |
|------------------------|---------------------------------|------------------------|------------------------|
|                       | Univariate analysis             |                       | Multivariate analysis  |
|                        | HR (95%CI)                      | p value               | HR (95%CI)             | p value               |
| Sex Female vs. Male    | 1.334 (1.109-1.605)             | 0.002                 | 1.263 (1.026-1.556)    | 0.028                 |
| Aspirin use Yes vs. no | 0.851 (0.674-1.075)             | 0.175                 |                        |                       |
| Age <68 vs. >68        | 1.033 (0.895-1.192)             | 0.661                 |                        |                       |
| Marital Status Yes vs. Others | 0.166 (0.098-0.280)       | <0.001                | 0.165 (0.094-0.289)    | <0.001                |
| Smoking                |                                  |                       |                        |                       |
| Non-smoker             |                                  |                       |                        |                       |
| Current smoker         | 1.900 (1.648-2.260)             | <0.001                | 2.390 (1.926-2.975)    | <0.001                |
| Former smoker          | 0.448 (0.336-0.596)             | <0.001                | 0.744 (0.537-1.031)    | 0.076                 |
| Alcohol use            |                                  |                       |                        |                       |
| Non-drinker            |                                  |                       |                        |                       |
| Current drinker        | 0.897 (0.794-1.129)             | 0.545                 | 0.615 (0.496-0.762)    | <0.001                |
| Former drinker         | 0.196 (0.152-0.254)             | <0.001                | 0.212 (0.162-0.276)    | <0.001                |
| History of cerebrovascular disease yes vs. others | 0.678 (0.531-0.866) | 0.002                  | 0.463 (0.662-1.126)    | 0.279                 |
| Diabetes yes vs. others | 0.166 (0.098-0.280)       | <0.001                | 0.165 (0.094-0.289)    | <0.001                |
| History of cardiovascular disease yes vs. others | 0.541 (0.432-0.678) | <0.001                | 0.541 (0.432-0.678)    | <0.001                |
| Metformin use yes vs. others | 0.341 (0.255-0.459) | <0.001                | 0.341 (0.255-0.459)    | <0.001                |

The bold values were applied to highlight P-values which had statistically significance (i.e. P<0.05).

| TABLE 4 | Association between aspirin intake and clinicopathological characteristics of 1121 BCa patients. |
|------------------------|---------------------------------|------------------------|------------------------|
|                        | Regular Aspirin use             |                       | Total                  |
|                        | No                              | Yes                    |                        |
| Gender                 |                                  |                        |                        |
| Male                   | 828                             | 100                    | 928                    |
| Female                 | 180                             | 13                     | 193                    |
| Age, years             |                                  |                        | <0.001                 |
| Less than 68           | 529                             | 33                     | 562                    |
| 68 or Greater          | 479                             | 80                     | 559                    |
| pT stage               |                                  |                        | 0.475                  |
| Tis-T1                 | 702                             | 75                     | 777                    |
| T2-T4                  | 306                             | 38                     | 344                    |
| Pathologic grade       |                                  |                        | 0.852                  |
| G1                     | 393                             | 41                     | 434                    |
| G2                     | 165                             | 19                     | 184                    |
| G3                     | 450                             | 53                     | 503                    |
| Lymph node status      |                                  |                        | 0.866                  |
| No                     | 951                             | 108                    | 1059                   |
| N1                     | 37                              | 4                      | 41                     |
| N2                     | 18                              | 1                      | 19                     |
| N3                     | 2                               | 0                      | 2                      |
| Distant metastasis     |                                  |                        | 0.693                  |
| M0                     | 979                             | 109                    | 1088                   |
| M1                     | 29                              | 4                      | 33                     |
| Type of surgery        |                                  |                        | 0.172                  |
| TURBT                  | 773                             | 81                     | 854                    |
| PC                     | 54                              | 4                      | 58                     |
| RC                     | 181                             | 28                     | 209                    |

The bold values were applied to highlight P-values which had statistically significance (i.e. P<0.05).
underwent radical prostatectomy (18.6%). The characteristics of bladder cancer patients, such as sex ($P=0.090$) and type of surgery ($P=0.172$), were not correlated with a history of aspirin intake. Similarly, tumor characteristics such as pT stage ($P=0.475$), pathologic grade ($P=0.852$), lymph node status ($P=0.866$), and distant metastasis ($P=0.693$) were also not correlated with a history of aspirin intake. However, age ($P<0.001$) was associated with a history of aspirin intake.

**The Association of Aspirin Intake and the Prognosis in Patients With BCa**

Of the 1121 patients, the median follow-up among survivors was 50.1 months. Seventy-nine patients (7.0%) died, and 235 patients (21.0%) experienced relapse. By KM plotter drawing, we did not find that patients with a history of aspirin intake had a markedly longer OS or RFS than those with no history of aspirin intake. To explore prognostic factors for bladder cancer, patient-specific and tumor-specific features, together with a history of aspirin intake, were incorporated into the Cox regression model. Notably, distant metastasis ($HR=2.611; 95\% CI=1.170-5.826$, $P=0.019$) and type of surgery ($HR=1.398; 95\% CI=1.066-1.833$, $P=0.015$) were significantly associated with OS (Table 5). Moreover, pT stage ($HR=1.728; 95\% CI=1.324-2.254$, $P<0.001$) was an independent predictor for RFS after multivariate analysis. However, a history of aspirin intake was not an independent factor for OS or RFS (Table 6). Stratified analysis by sex showed no correlation between aspirin intake and the recurrence of BCa for either male patients ($P=0.325$) or female patients ($P=0.617$). Furthermore, aspirin intake was not significantly associated with overall survival in male ($P=0.071$) or female patients ($P=0.646$) with BCa. Stratified analysis by sex showed no correlation between aspirin intake and the recurrence of BCa for either male patients ($P=0.325$) or female patients ($P=0.617$). Stratified analysis by age showed no change between aspirin intake and the recurrence of BCa for both patients younger than 68 years old ($P=0.489$) and patients older than 68 years ($P=0.916$). Furthermore, aspirin intake was not significantly associated with overall survival in patients older than 68 years ($P=0.318$). Interestingly, aspirin intake ($HR=3.876; 95\% CI=1.326-11.325$, $P=0.019$) and type of surgery ($HR=1.685; 95\% CI=1.131-1.313$, $P=0.010$) were significantly associated with OS in BCa patients younger than 68 years old after Cox multivariate regression analysis.

**Meta-Analysis**

**Study Identification and Selection**

The selection process following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) reporting guideline for the association of aspirin intake with the risk and prognosis of BCa is presented in Figure 2. Initially, the database search retrieved 1107 relevant publications. After screening the titles, abstracts and full texts of these articles, we excluded duplicate studies and other studies for various reasons (reviews/editorials, animal/molecular biology studies, or not relevant to our analysis etc.). Thus, in the final analysis, we included 19 studies about the relation of aspirin intake risk of

---

**TABLE 5 |** Univariate and multivariate Cox regression model for overall survival (OS) including known parameters in 1121 BCa patients treated with surgery.

| Overall Survival | Univariate analysis | Multivariate analysis |
|------------------|---------------------|----------------------|
|                  | HR (95%CI)          | P value              | HR (95%CI)          | P value              |
| Gender           | 2.344 (1.018-5.397) | 0.045                | 2.137 (0.924-4.944) | 0.076                |
| Age              | 1.697 (1.077-2.675) | 0.023                | 1.392 (0.869-2.229) | 0.169                |
| pT stage         | 1.810 (1.157-2.832) | 0.009                | 1.218 (0.728-2.037) | 0.453                |
| Pathologic grade | 1.201 (0.939-1.535) | 0.145                |                      |                      |
| Lymph node status| 0.662 (0.273-1.606) | 0.362                |                      |                      |
| Distant metastasis| 3.552 (1.626-7.760) | 0.001                | 2.611 (1.170-5.826) | 0.019                |
| Type of surgery  | 1.598 (1.263-2.023) | <0.001               | 1.398 (1.066-1.833) | 0.015                |
| Aspirin use      | 2.045 (1.100-3.802) | 0.024                | 1.653 (0.871-3.137) | 0.124                |

The bold values were applied to highlight P-values which had statistically significance (i.e. $P<0.05$).

---

**TABLE 6 |** Univariate and multivariate Cox regression model for recurrence-free survival (RFS) including known parameters in 1121 BCa patients treated with surgery.

| Overall Survival | Univariate analysis | Multivariate analysis |
|------------------|---------------------|----------------------|
|                  | HR (95%CI)          | P value              | HR (95%CI)          | P value              |
| Gender           | 1.070 (0.753-1.521) | 0.706                | 1.728 (1.324-2.254) | <0.001               |
| Age              | 1.284 (0.992-1.663) | 0.058                | 1.103 (0.954-1.227) | 0.186                |
| pT stage         | 1.812 (1.396-2.351) | <0.001               | 1.702 (0.925-3.132) | 0.087                |
| Pathologic grade | 1.173 (1.016-1.353) | 0.029                |                      |                      |
| Lymph node status| 1.321 (0.960-1.819) | 0.057                |                      |                      |
| Distant metastasis| 1.986 (1.055-3.551) | 0.033                |                      |                      |
| Type of surgery  | 1.133 (0.971-1.321) | 0.112                |                      |                      |
| Aspirin use      | 1.170 (0.772-1.774) | 0.459                |                      |                      |

The bold values were applied to highlight P-values which had statistically significance (i.e. $P<0.05$).
BCa, 4 studies about outcome of BCa surgery and 11 studies about the relation of aspirin intake and prognosis of patients with BCa based on the inclusion criteria.

Characteristics of the Studies
The characteristics of the 19 included trials (29–47) about the relation of aspirin intake and risk of BCa were provided in Table 7. These trials were published between 1989 and 2021. Of the 20 included articles which include our studies, finally contains 31 studies. In these studies, nine were conducted in the North America (29–31, 33–36, 44, 45), four in Asia (38, 41, 42), four in Europe (32, 37, 46, 47), and three in multi-regions (39, 40, 43). Among all studies enrolled, eleven were cohort studies (29, 30, 34, 38–42, 44–46), and eight were case-control studies (31–33, 35–37, 47) containing this study. The given sample size of the trials ranged from 839 to 612509, with a total of more than 39524 patients with BCa. The characteristics of the four included trials (48–51) involving the relationship of aspirin intake and clinical course of bladder tumor surgery were provided in Table 8. These researches were published from 2013 to 2019 and from the USA (50), Italy (51), France (49) and Germany (48), respectively. The the characteristics of the eleven included trials regarding the impact of aspirin intake on the prognosis of patients with BCa were presented in Table 9. The selected studies were published between 2004 and 2021. Combined with our study, eight studies originated from the USA (52, 53, 55–60), one was from Italy (61), one was from India (54) and one was from multi-regions (39). The sample size of the trials ranged from 43 to 139896. Among the twelve studies enrolled, eleven were cohort studies (39, 52–61), and only one was case-control study.

The Association Between Aspirin Intake and the Risk of Bladder Cancer

Overall Analysis

31 studies reported the effect estimates of the association between aspirin intake and the occurrence of BCa. The fixed-effects model was applied because the test for heterogeneity was not significant ($I^2=0.00\%, P=0.586$). We found that patients with aspirin intake did not have a significantly lower risk of BCa than those without aspirin intake (RR=1.007, 95% CI=0.975–1.041, $P=0.671$). The sensitivity analysis demonstrated that no single trial had significantly influenced the pooled RR (Figure 3). This result
TABLE 7 | Main characteristics of individual studies included in the meta-analysis on impact of aspirin intake on risk of BCa.

| First author (year) | Region | Study type | Study period | Age | Total number | BCa Cases | Dose of use | Frequency/duration of use | Adjusted HR/RR/OR (95% CI) |
|---------------------|--------|------------|--------------|-----|--------------|-----------|------------|--------------------------|--------------------------|
| Loomans-Kropp HA (39) | Multi-regions | Cohort study; Prospective | 1993-2001 | 74 | 139896 | 1751 | NA | ≥3 times/week | 0.99 (0.90-1.10) |
| Orchard SG (40) | Multi-regions | Cohort study; Prospective | 1990-2018 | >18 | 19030 | 142 | 100mg/day | NA | 1.02 (0.59-1.77) |
| Sung JJ (41) | China | Cohort study; Retrospective | 2000-2013 | 67.5 | 162509 | 5291 | 80mg/day | ≥6 months | 0.93 (0.83-1.05) |
| Tsoi K (38) | China | Cohort study; Retrospective | 2000-2004 | 67 | 1355 | 690 | NA | ≥1 times/week for ≥6 months | 1.21 (0.87-1.68) |
| Guercio V (37) | Italy | Case control; Cohort study; Retrospective | 2003-2014 | >40 | 320613 | 2121 | NA | NA | 1.05 (0.87-1.27) |
| Stegeman I (43) | Multi-regions | Others | 2006-2015 | 85 | NA | NA | NA | NA | 0.94 (0.64-1.38) |
| Brasky TM (44) | USA | Cohort study; Prospective | 1993-2010 | 79 | 126889 | 154 | ≤100mg/day | ≥2 times/week for ≥2 weeks | 1.12 (0.63-1.98) |
| Shih C (36) | USA | Case control; Retrospective | 2000-2010 | 50 | 77048 | 385 | Low use | 81mg | 1–3 days/week for <4 years | 0.87 (0.64-1.18) |
| | | | | | | | | | ≤325mg/day | Regular use |
| | | | | | | | | ≤325mg/day | Aspirin NA |
| Daugherty SE (35) | USA | Case control; Retrospective | 1993-2001 | 63.5 | 508842 | 2489 | NA | <2 times/week | 1.03 (0.92-1.15) |
| Genkinger JM (34) | USA | Cohort study; Retrospective | 1986-2002 | 75 | 49448 | 607 | NA | ≥2 times/week | 1.04 (0.91-1.19) |
| Fortuny J (33) | USA | Case control; Retrospective | 1997-2000 | 74 | 839 | 376 | NA | ≥4 times/week for ≥1 month | 0.60 (0.40-0.90) |
| Jacobs EJ (45) | USA | Cohort Study; Prospective | 1992-2003 | >50 | 148113 | 18127 | ≥325mg/day | <4 years | 1.00 (0.73-1.38) |
| | | | | | | | | ≤325mg/day | Nonregular use |
| | | | | | | | | ≤325mg/day | 1 month |
| Fortuny J (32) | Spain | Case control; Retrospective | 1997-2000 | 20 | 1987 | 958 | NA | <2 times/week | 1.03 (0.86 - 1.24) |
| Frits S (46) | Denmark | Cohort study; Prospective | 1989-1997 | 70 | 29470 | 134 | 75-150mg/day | 1 time/day for 3 months | 0.85 (0.66-1.09) |
| Castelao JE (31) | USA | Case control; Retrospective | 1987-1996 | 58 | 3028 | 1514 | NA | ≥2 times/week for ≥1 month | 1.20 (1.00-1.40) |
| Pommer W (47) | Germany | Case control; Retrospective | 1990-1995 | NA | 2180 | 571 | NA | Male: 1.21 (0.87-1.68) Female: 1.20 (0.70-1.50) |
| Schreinemachers DM (33) | USA | Cohort study; Prospective | 1982-1987 | 25 | 12668 | 35 | NA | ≥1 time/month | 1.06 (0.54-2.08) |
| Paganini-Hill A (29) | USA | Cohort study; Prospective | 1981-1988 | 73 | 13967 | 96 | NA | <1 time/day | 1.21 (0.63-1.99) |
| | | | | | | | | ≥1 time/day | Male: 1.12 (0.63-1.99) Female: 0.89 (0.26-3.10) |
| This study | China | Case control; Retrospective | 2002-2019 | 68 | 3363 | 1121 | ≥80mg/day | ≥1 month | 0.85 (0.67-1.08) |

exhibited a low probability of publication bias, as determined by Begg’s test (P=1.000) and Egger’s test (P=0.709, Figure 3B). However, low dose (<100mg/day) aspirin intake impacted on risk of BCa (RR=1.072, 95% CI=1.004-1.145, P=0.038).

Sensitivity Analysis
The effects for heterogeneity of each study were evaluated by leave-one-out sensitivity analysis. As shown in Figure 4A, the forest plots were equally applied, indicating that the identified studies in our meta-analysis had no significant influence to heterogeneity. Additionally, the respective values of I² and P_Q were enriched in Figure 4B. There were low heterogeneity after leaving the individual single study out, suggesting that the meta-analysis based on the pooled studies was credible.

Subgroup Analysis by Whether Regular Use of Aspirin
Fixed-effects model was applied on account of little heterogeneity (I²=0.8%, P=0.451). There were no dependency between aspirin use and BCa in the group of regular users (RR=1.012,
### TABLE 8 | Main characteristics of eligible studies collected in the meta-analysis on effect of aspirin intake on outcome of surgery for BCa.

| First author | Region | Study type | Study period | Age | BCa Cases | Surgical approach | Dose of use | Frequency/Duration of use | Adjusted HR/RR/OR (95% CI) |
|--------------|--------|------------|--------------|-----|-----------|------------------|-------------|--------------------------|----------------------------|
| Wessels F (48) | Germany | Retrospective cohort study | 2011-2017 | 65 | 461 | RC | NA | NA | BTR: 1.12 (0.80-1.57) IACR: 1.48 (0.77-2.86) |
| Prader R (49) | France | Retrospective case-control study | 2013-2015 | 53-83 | 234 | TURBT | ≥75mg/day | NA | BTR: 1.38 (0.09-21.70) IACR: 1.15 (0.36-3.64) IHO: 4.12 (0.17-99.83) |
| Ghali F (50) | USA | Retrospective case-control study | 2011-2014 | 70 | 708 | TURBT | NA | NA | IACR: 0.38 (0.15-0.92) |
| Picozzi S (51) | Italy | Cohort study | 2007-2012 | 74-68 | 158 | TURBT | 100mg/day | NA | BTR: 1.94 (0.36-10.39) IHO: 1.46 (0.25-8.55) |

IACR, Incidence of any-cause rehospitalization; BTR, Blood transfusion rate; IHO, Incidence of hemostatic operation; TURBT, Transurethral resection of bladder tumor; RC, Radical cystectomy.

### TABLE 9 | Main characteristics of eligible studies collected in the meta-analysis on effect of aspirin intake on prognosis of BCa.

| First author | Region | Study type | Study period | Age | Total number | BCa cases | Dose of use | Frequency/Duration of use | Reported end-points |
|--------------|--------|------------|--------------|-----|--------------|-----------|-------------|--------------------------|---------------------|
| Loomans-Kropp HA (39) | Multi-regions | Cohort study; Prospective | 1993-2001 | 65 | 139896 | 1751 | NA | ≥ 3 times/week | CSS: 0.67 (0.51-0.88) CSS: 0.75 (0.58-0.98) |
| Li P (52) | USA | Cohort study; Retrospective | 2016 | 65 | 63308 | 2600 | NA | 3 times/week | NA |
| Lyon TD (53) | USA | Cohort study; Retrospective | 2007-2016 | NA | 1061 | 1061 | 25mg/day 81mg/day 325mg/day 650mg/day | 3 months | CSS: 0.64 (0.45-0.89) OS: 0.70 (0.53-0.93) MFS: 0.96 (0.68-1.36) |
| Gupta R (54) | India | Cohort study; Prospective | 2015-2017 | 58 | 103 | 103 | 75mg/day | ≥3 months | RFS: 0.74 (0.45-1.24) |
| Singla N (55) | USA | Cohort study; Prospective | 2006-2012 | 73 | 203 | 99 | 81mg/day 325mg/day | NA | CSS: 3.14 (0.37-26.91) OS: 1.91 (0.69-5.27) RFS: 1.05 (0.64-1.74) |
| Pastore AL (56) | Italy | Cohort study; Retrospective | 2008-2013 | 62 | 574 | 574 | 100mg/day | ≥2 years | CSS: 1.05 (0.45-2.42) |
| Lipsky MJ (57) | USA | Cohort study; Retrospective | 2001-2011 | 56 | 224 | 224 | NA | NA | RFS: 2.41 (1.08-5.35) |
| Jacobs EJ (58) | USA | Cohort study; Prospective | 1997-2008 | NA | 100139 | 302 | Baby low dose; Adult strength dose | ≥1 months | OS: 0.75 (0.48-1.16) RFS: 0.91 (0.751.0) |
| Boorjian SA (59) | USA | Cohort study; Retrospective | 1990-2006 | 57-75 | 907 | 907 | NA | NA | OS: 1.91 (0.64-1.74) |
| Gee JR (60) | USA | Cohort study; Retrospective | 1991-2003 | 67 | 43 | 43 | 81mg/day 325mg/day | NA | RFS: 0.74 (0.45-1.24) |
| Ratnasinghe LD (61) | USA | Cohort study; Prospective | 1982-1992 | 25-74 | 22794 | 40 | NA | NA | OS: 3.36 (1.03-10.97) |
| This study | China | Case control; Retrospective | 2002-2019 | 68 | 1121 | 1121 | 80mg/day | ≥1 months | OS: 1.65 (0.871-3.137) RFS: 1.17 (0.772-1.774) |

OS, Overall survival; CSS, Cancer-specific survival; PFS, Progression-free survival; RFS, Recurrence-free survival; MFS, Metastasis-free survival.
95% CI=0.974-1.053, P=0.535) and nonregular users (RR=1.026, 95% CI=0.943-1.116, P=0.549), respectively. Begg’s test (P=0.802) and Egger’s funnel plot asymmetry test (P=0.624) manifested that there was no significant publication bias (Figure 5).

**Subgroup Analysis by the Mean Duration of Use of Aspirin**
Random effects model has been arranged because of strong heterogeneity (I²=75.1%, P<0.001). The crowd with a mean duration of aspirin use was less than 6 months and regular users were used for more than 6 months (RR=1.043, P=0.785).

**FIGURE 3** | Forest plot (A) and funnel plot (B) showing the relationship between aspirin intake and the risk of bladder cancer in the overall analysis. The x-coordinate scale of solid lines perpendicular to the X-axis is 1. Each horizontal segment parallel to the X-axis and the point estimate represent the position of the point of the OR, and the size represents the weight of the study, which represents the percentage of the results of each study in the overall results. The intersection of the horizontal segment and the solid vertical line indicates that the study results are not statistically significant. Diamonds represent the overall effect of the estimate using the Mantle-Haenszel fixed-effects model. The visual examination of the funnel plot showed no apparent asymmetry, indicating that the publication bias was small and that the effect on the combined effect was negligible.

**FIGURE 4** | The leave-one-out sensitivity analysis for overall analysis. The forest plot (A, B) table showed the effects for heterogeneity of each study.
duration of use aspirin ≥5 years (RR=0.923, 95% CI=0.806-1.054, \( P=0.245 \)) and even <5 years (RR= 0.901, 95% CI=0.771-1.06, \( P=0.192 \)) were not associated with bladder cancer risk. There was no proof of significant publication bias by inspection of the funnel plot and formal statistical tests (Egger’s test, \( P=0.064 \); Begg’s test, \( P=0.272 \); Figure 6).

Subgroup Analysis by Sex

As a slight degree of heterogeneity was found (\( I^2=38.0\% \), \( P=0.088 \)), so a fixed-effects model was used. The results indicated no correlation between aspirin intake and BCa in either the male population (RR=1.028, 95% CI=0.958-1.102, \( P=0.449 \)) or the female population (RR=1.014, 95% CI=0.873-1.178, \( P=0.856 \)). Both Begg’s test (\( P=0.837 \)) and Egger’s funnel plot asymmetry test (\( P=0.971 \)) indicated that there was no significant publication bias (Figure 7).

Subgroup Analysis by Smoking Exposure

Smoking exposure in bladder cancer risk assessment is extremely necessary. There was no testimony for heterogeneity (\( I^2=0.0\% \), \( P=0.613 \)). There were no apparent pertinence of aspirin and BCa embodied in the groups of non-smokers (RR=0.966, 95% CI=0.845-1.104, \( P=0.610 \)), former smokers (RR=1.073, 95% CI=0.989-1.165, \( P=0.091 \)) and current smokers (RR=0.896,
95% CI=0.777-1.032, \( P=0.128 \), the overall analysis results also showed no difference (RR=1.012, 95% CI=0.951-1.078, \( P=0.707 \)). Publication bias was not obvious (Egger’s test, \( P=0.817 \); Begg’s test, \( P=0.381 \); Figure 8).

**Subgroup Analysis by Research Region**
Meta-analysis using a fixed-effects model (\( I^2=0.0\%, \ P=0.590 \)) suggested that aspirin intake had no significant influence on the prevention of BCa in multi-regions (RR=0.974, 95% CI=0.910-1.043, \( P=0.456 \)), Asian populations (RR=0.991, 95% CI=0.902-1.088, \( P=0.850 \)), European populations (RR=1.112, 95% CI=0.996-1.242, \( P=0.059 \)) and North American populations (RR=1.000, 95% CI=0.948-1.055, \( P=0.990 \)). There was no evidence of significant publication bias by inspection of the funnel plot and formal statistical tests (Egger’s test, \( P=0.703 \); Begg’s test, \( P=0.961 \); Figure 9).

**Subgroup Analysis by Study Type**
Within 18 cohort studies, aspirin intake was not linked to a decreased risk of BCa (RR=1.012, 95% CI=0.972-1.053, \( P=0.565 \)). There was no evidence for heterogeneity (\( I^2=0.0\%, \ P=0.590 \)). Moreover, when the data collected from 13 case-control studies (16, 17) were pooled (Figure 10), there was no statistically significant association between aspirin administration and BCa (RR=1.000, 95% CI=0.944-1.058, \( P=0.989 \)). No association between aspirin intake and BCa was also examined in other study type subgroup (RR=1.007, 95% CI=0.975-1.041, \( P=0.752 \)). Begg’s test (\( P=0.752 \)) and Egger’s test (\( P=0.744 \)) showed that the
funnel plot distribution was symmetrical and that there was no significant publication bias.

The Association Between Aspirin Intake and Outcomes of Surgery for BCa

The Association Between Aspirin Intake and Intraoperative Conditions in Patients With BCa

Four studies suggested the relationship between aspirin intake and intraoperative conditions, including mean loss of hemoglobin, mean duration of operation and blood transfusion rate. The low and moderate heterogeneity was observed in blood transfusion rate group ($I^2=0.0\%$, $P=0.814$) and the mean duration of operation ($I^2=68.0\%$, $P=0.08$) group, using fixed-effects models; while high heterogeneity was determined in exploring the association between aspirin intake and the mean loss of hemoglobin ($I^2=81.0\%$, $P=0.006$) for BCa patients, and a random-effects model was applied. Compared with control group, aspirin intake had no impact on loss of hemoglobin with a combined MD of 0.08 (95% CI=-0.32-0.48, $P=0.68$) and the mean duration of operation with a combined MD of -2.36 (95% CI=-22.36-17.63, $P=0.820$). Moreover, there was no difference in blood transfusion rate during the resection of BCa.
between the aspirin group and the control group (RR=1.147, 95% CI=0.826-1.593, \( P=0.412 \)).

**The Association Between Aspirin Intake and Postoperative Complications in Patients With BCa**

Three studies suggested the relationship between aspirin intake and postoperative complications including incidence of any-cause rehospitalization and hemostatic operation. As low heterogeneity was detected in any-cause rehospitalization (I^2=65.4%, \( P=0.056 \)) and hemostatic operation (I^2=0.0%, \( P=0.577 \)), fixed-effects models were used. Compared to control group, aspirin intake had no impact on incidence of any-cause rehospitalization (RR=1.12, 95% CI=0.80-1.57, \( P=0.797 \)) and incidence of hemostatic operation (RR=1.86, 95% CI=0.40-8.73, \( P=0.430 \)). The above results showed in Figures 11A–C.

The Impact of Aspirin Intake on the Prognosis of Patients With Bladder Cancer

**Aspirin Intake and the Survival of Patients With Bladder Cancer**

Among 11 articles and our study including a total of 8825 BCa patients with survival data, 6 studies investigated the relationship between aspirin intake and overall survival (OS) in BCa patients, and 4 studies reported cancer-specific survival (CSS). The random-effects model was used (Figure 12), as higher heterogeneity was detected among these studies (\( P\)-value for heterogeneity<0.001; I^2=73.5%). No significantly decreased levels of OS were observed in BCa patients who consumed aspirin compared with the controls, with a combined HR of 1.026 (95% CI=0.770-1.368, \( P=0.859 \)). In contrast, aspirin intake had significant effects on the CSS of BCa patients (HR=0.749, 95% CI=0.646-0.869, \( P<0.001 \)).

**FIGURE 11** | Forest plot (A) and funnel plot (B) showing the association of aspirin intake and the outcome of surgery, including blood transfusion rate, incidence of any-cause rehospitalization and the incidence of hemostatic operation; Forest plot (C) showing the association of aspirin intake and the outcome of surgery, including the mean duration of operation and mean loss of hemoglobin for BCa patients.
Aspirin Intake and Recurrence, Progression and Metastasis of Patients With Bladder Cancer

7 studies that reported the effect estimates of the association between aspirin intake and the recurrence, progression and metastasis of BCa. The random-effects model was applied, as the test for heterogeneity was significant ($I^2=55.5\%$, $P=0.013$). We found that patients with aspirin intake did not have a significantly lower risk of BCa recurrence (HR=0.936, 95% CI=0.667-1.313, $P=0.701$), progression (HR=0.922, 95% CI=0.570-1.489, $P=0.739$) and metastasis (HR=0.960, 95% CI=0.679-1.358, $P=0.817$) than those without aspirin intake, as shown in Figure 13A. This result exhibited a low probability of publication bias, as determined by Egger’s test ($P=0.798$, Figure 13B).

DISCUSSION

Aspirin is a non-steroidal anti-inflammatory drug with a long history. It is suitable for antipyretic and analgesic use and is widely used in the prevention of cardiovascular thrombosis (18). Recent studies have found that the long-term regular use of aspirin can significantly reduce the incidence of colorectal cancer, gastric cancer, liver cancer and other malignant tumors (62–65). A population-based case-control study analyzed data from 1121 BCa cases and 2242 controls in New Hampshire and found that aspirin significantly reduced the risk of BCa, especially for tumors containing TP53 mutations (33). Similarly, Castelao J et al. (31) illustrated that there was a
nonsignificant trend towards increased BCa risk in people with a longer duration of painkillers than in people who do not use painkillers, and regarding the effect of the correlation of different types of analgesics and BCa risk on the direction and strength of the obvious difference, aspirin showed weaker role. However, in a cohort study by Genkinger JM et al. (34). In the USA, there was no association between the frequency and dose of aspirin and BCa risk, which was not altered by known risk factors such as age, smoking or total fluid intake. To compensate for the lack of related research focusing on the population in Northeast China, a retrospective single-center case-control study analyzed data from 1121 BCa cases and 2242 controls in Northeast China was established to explore the association between the incidence of BCa and aspirin intake. Although we found several susceptibility factors were associated with strong risk of BCa, including gender (OR=1.263; \( P=0.028 \)); marital status (OR=0.165; \( P<0.001 \)); current smoking status (OR=2.360; \( P<0.001 \)); current alcohol use (OR=0.615; \( P<0.001 \)); former alcohol use (OR=0.314; \( P<0.001 \)) and history of cardiovascular disease (OR=0.212; \( P<0.001 \)).

Interestingly, in our case control study, subgroup analyses stratified by sex showed that there was no correlation between aspirin intake and the risk of BCa in female patients, however, the male population who regularly took aspirin had a lower incidence of BCa (OR=0.748; \( P=0.021 \)). While considering the limited sample size and ethnic specificity, several explanations may help us better understand the above result. Androgens/Androgen Receptor (AR) system is considered as a central link to down-regulate ARs to inhibit the Androgens/Androgen Receptor system and subsequently suppress incidence of BCa, which need further molecular biological validation.

Meanwhile, it should be noted that subgroup analyses stratified by smoking status in our case control study found a significant reduction in the risk of BCa in current smokers with aspirin intake (OR=0.522; \( P=0.002 \)), not in nonsmokers (\( P=0.252 \)) or former smokers (\( P=0.807 \)). Smoking and daily aspirin use are both risk factors for cancer. Some research indicates that aspirin usage in smokers is correlated with an increased risk of developing cancer, which could nullify the protective function of aspirin (72–74). Wang X et al. (73) found that aspirin use was related to a 29% lower CRC risk among never-smokers, compared to 17% lower CRC risk among smokers above median pack-years, indicating that heavy smokers could not be more favorable for protective role of aspirin against colorectal cancer than non-smokers. As cigarette was found to be more strongly associated with colorectal carcinoma which arise from serrated polyp pathway related to microsatellite instability, it was related to an increased risk of polyps in the left colon (75). While aspirin intake lowered the risk of serrated polyps in the right colon, indicating different subsites of colon cancer may be influenced by aspirin and smoking (75). As playing role on platelet hyper-reactivity, smoking was strongly associated with increased risk of aspirin resistance, suggesting that the effect of aspirin may rely on independent carcinogenesis or progression (76) pathways of colorectal carcinoma among smokers and non-smokers. In breast cancer, cigarette smoking and aspirin/NSAID use interacted to affect breast cancer-specific mortality. Slattery ML et al. (76) reported that the strongest associations were observed for the interaction between cigarette smoking and aspirin intake with JAK/STAT signaling pathway including JAK2, STAT3, STAT5a, and STAT5b which were critical for cell development, cell proliferation, and apoptosis of breast cancer. As SOCS suppressed the signaling. Nicotine which were found in cigarette smoke condensates and activated the JAK2/STAT3 pathway (77), rs3816997 of SOSC2 may interacted with cigarette smoking and aspirin intake.

The prognostic value of aspirin use on monitor the intraoperative and postoperative outcome of BCa patients was also attracted increasing attention from scholars. After follow up 1121 BCa patients, we did not find that patients with a history of aspirin intake had a markedly longer overall or recurrence-free survival than those with no history of aspirin intake. Cox regression model did not indicate a history of aspirin intake was not an independent factor for overall or recurrence-free survival. Stratified analysis by sex showed no correlation between aspirin intake and the recurrence or survival of BCa for either male or female patients. Interestingly, we found that aspirin intake (HR=3.876; \( P=0.019 \)) and type of surgery (HR=1.685; \( P=0.010 \)) were significantly associated with overall survival in BCa patients younger than 68 years old. In the people who regularly used aspirin, majority of them has the history of coagulation abnormalities, consisting of platelet abnormalities and fibrinolysis (78–80). And coagulation abnormalities have
long been closely related with the cardiovascular or cerebrovascular diseases, which are mostly found in the elderly and increased overall mortality considerably (81, 82). In addition, various of selection for statistics method may cause discrepancy the analysis outcomes.

Relative to our negative result about the effects of aspirin on tumor recurrence, a case-control study from Italy and a retrospective study from the USA showed a significant association between aspirin and recurrence in patients with BCa (55, 61). In the study of Gee JR (55), the 5-year RFS of aspirin users was 64.3%, which was significantly higher than that of non-aspirin users (26.9%), even after multivariate analysis adjusted for other factors. Considering the effect of aspirin on the survival rate of cancer patients, Lyon TD’s study (59) found that daily aspirin significantly improved survival outcomes after radical resection. It has also been observed that patients receiving low-dose aspirin had significantly better outcomes than patients receiving high-dose aspirin and those without aspirin. In contrast, a cohort study from the United States found no significant association between aspirin use and the overall survival of BCa patients (52). In addition, a prospective study by Singla N et al. (58) showed that the use of aspirin does not affect the survival of patients with any tumors, including CSS, OS, recurrence-free survival and cystectomy-free survival, regardless of the dose (81 or 325 milligrams a day). In response to these mixed findings, we performed a meta-analysis to investigate the impact of aspirin intake on the prognosis of patients with BCa and found that aspirin had no significant effects on the OS and CSS of BCa patients. In addition, patients with aspirin intake did not have a significantly lower risk of BCa recurrence, progression and metastasis than those without aspirin intake. We also found that there was no difference in blood transfusion rate, loss of hemoglobin, mean duration of operation, any-cause rehospitalization and incidence of any-cause rehospitalization during the resection of BCa between the aspirin group and the control group. Until now, available data have not supported a connection between aspirin exposure and the intraoperative situation and postoperative prognosis of BCa patients despite few prior studies.

Our limitations are as follows: one limitation is that this case-control study is a single-center study, which may lead to certain bias or heterogeneity. To the greatest extent possible to avoid such shortcomings or loopholes, we performed a meta-analysis to investigate the relationship between aspirin intake and the risk and prognosis of BCa. Some included studies did not provide available values of HR, RR or OR from multivariate analysis, so we performed calculations from the univariate data and compared them through formula calculations. The statistical methods we used cannot replace all the research methods. The conclusions we obtained without correlation are limited to the scope of our research, which may have some statistical errors (83, 84). Second, we only focused on researching patients who regularly consumed aspirin. Due to the limited available information from clinical data, stratification analysis according to different doses or durations was not conducted. The above factors may influence the results regarding the connection between the risk of BCa and the use of aspirin (10), which will be one of the focuses of our future research. Third, both our case-control study and meta-analysis showed no differences between aspirin intake and the risk and prognosis of BCa. However, previous in vitro studies have shown that aspirin may play a role as a chemopreventive agent in the OH-BBN/BDF BCa model (85), which suggests that there is heterogeneity between human epidemiological experiments and in vitro cell experiments.

CONCLUSION AND OUTLOOK

Although aspirin has been predicted to be protective against various tumors, differences in tumor origin and tissue specificity are bound to influence the results, which needed virtual simulated human microenvironment to explore whether aspirin can prevent or monitor BCa. Meanwhile, multi-center, large-sample, prospective studies are also needed. Advances in cancer biology clearly indicate that the development of malignant tumors is the result of complex interactions and the integration of gene expression, proteome and metabolome changes, involving genetics, microbes, diet, drugs (86, 87), and other factors such as different living conditions, exposure factors and ethnic differences (88). In the age of precision oncology, individual cancer treatment should be personalized based on genetic and environmental factors. In addition, aspirin, as a sensitizer, can increase the therapeutic effect of chemotherapy for cancers of the colon and stomach, while there are few studies in the urinary system, which will be a promising research direction. As a continuation of this study, it is necessary to further explore pathological examinations, immune parameters, tumor molecular markers and other aspects from the database, which contributes greatly to the development of BCa treatment.

DATA AVAILABILITY STATEMENT

The datasets generated for our case-control study are available on request to the corresponding authors. Additionally, publicly available datasets for meta-analysis in our study could be searched in the PubMed, Embase, Ovid Medicine, Cochrane Library and Scopus databases.

ETHICS STATEMENT

This study was approved by the institutional review committee of the Second Affiliated Hospital of Dalian Medical University and written informed consent was obtained from each patient or their next of kin (Approval Ref. No. KY2018-120).

AUTHOR CONTRIBUTIONS

BF, XL, and GW contributed to the study concept and design, undertook project leadership and guaranteed this work. YH, HL, HJ, MFS, ST, WX, QL, TH, ZY, and RZ were responsible for data
collection and interpretation. ZY and RZ controlled quality of data and algorithms. BF, AM, YH, HJ, and ST analyzed data and interpreted the data. BF, GW, HL, HJ, and MS wrote the first draft of the manuscript. BF, HY, and AM reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank professor Xueyan Xia of Dalian Medical University Library for her generous support and direction. In addition, we would like to thank all members of the study team, the patients and their family for their contributions with our work.

REFERENCES

1. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. *Eur Urol* (2016) 69:300–10. doi: 10.1016/eururo.2015.08.037
2. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *Eur Urol* (2017) 71:96–108. doi: 10.1016/eururo.2016.06.010
3. Smith ND, Prasad SM, Patel AR, Weiner AB, Pariser JJ, Razmaria A, et al. Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors. *J Urol* (2016) 195:290–6. doi: 10.1016/j.juro.2015.07.091
4. Galinsky MD. Bladder Cancer in 2017: Advancing Care Through Genomics and Immune Checkpoint Blockade. *Nat Rev Urol* (2018) 15:71–2. doi: 10.1038/nrrurol.2017.199
5. Pang C, Guan Y, Li H, Chen W, Zhu G. Urologic Cancer in China. *Ipn J Clin Oncol* (2016) 46:497–501. doi: 10.1093/ijc/opyw034
6. Liu X, Jiang J, Yuan C, Sun Y, Tang J, et al. Secular Trends in Incidence and Mortality of Bladder Cancer in China, 1990-2017: A Joinpoint and Age-Period-Cohort Analysis. *Cancer Epidemiol* (2019) 69:105–103. doi: 10.1016/j.canep.2019.05.011
7. Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EUA Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. *Eur Urol* (2017) 71:462–75. doi: 10.1016/eururo.2016.06.020
8. van Kessel K, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart N, Beukers W, et al. Nitrate and Nitrite and Bladder Cancer in Northern Europe. *Int J Cancer* (2017) 140:2480–8. doi: 10.1002/ijc.31028
9. van Kessel K, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart N, Beukers W, et al. Ingested Nitrate and Nitrite and Bladder Cancer in Northern Europe. *Int J Cancer* (2017) 140:2480–8. doi: 10.1002/ijc.31028
10. Fan et al. Aspirin Intake and Bladder Cancer Risk: The Japan Public Health Center-Based Prospective Study. *Int J Cancer* (2017) 141:2480–8. doi: 10.1002/ijc.31028
11. Hsu J, Chen JR, Cui Y, Zhu YW, Ren WB, Zhou X, et al. Association of Metformin Intake With Bladder Cancer Risk and Oncologic Outcomes in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis. *Med (Baltimore)* (2018) 97:e11596. doi: 10.1097/MD.0000000000011596
12. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. *Circulation* (2016) 134:1579–94. doi: 10.1161/CIRCULATIONAHA.116.023164
13. Song Y, Zhong X, Gao P, Zhou C, Shi J, Wu Z, et al. Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review. *Front Endocrinol (Lausanne)* (2020) 11:1133. doi: 10.3389/fendo.2020.00003
14. Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, et al. Aspirin Use and Reduced Risk of Pancreatic Cancer. *Cancer Epidemiol Biomarkers Prev* (2017) 26:68–74. doi: 10.1158/1055-9965.EPI-16-0508
15. Yao MA. An Introduction to Aspirin, NSAIDs, and COX-2 Inhibitors for the Primary Prevention of Cardiovascular Events and Cancer and Their Potential Preventive Role in Bladder Carcinogenesis: Part II. *Semin Urol Oncol* (2001) 19:306–16.
16. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-Aspirin Inhibits MCF-7 Breast Cancer Cell Growth: Effects on COX-2 Expression and Wt/beta-Catenin/TCF-4 Signaling. *Biochem Pharmacol* (2009) 78:1298–304. doi: 10.1016/j.bcp.2009.06.014
17. Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, Mcallister SS, et al. Aspirin Suppresses Growth in P3K-Mutant Breast Cancer by Activating AMPK and Inhibiting Mtorc1 Signaling. *Cancer Res* (2017) 77:790–801. doi: 10.1158/0008-5472.CAN-16-2400
18. Pozzoli G, Petrucci G, Navarra P, Marei HE, Cenciarelli C. Aspirin Inhibits Proliferation and Promotes Differentiation of Neuroblastoma Cells via p21Waf1 Protein Up-Regulation and Rb1 Pathway Modulation. *J Cell Mol Med* (2019) 23:7087–87. doi: 10.1111/jcm.14610
19. Di Masi M, Bosetti C, La Vecchia C, Garavello W, Montella M, Libra M, et al. Regular Aspirin Use and Nasopharyngeal Cancer Risk: A Case-Control Study in Italy. *Cancer Epidemiol* (2015) 39:545–7. doi: 10.1016/j.canep.2015.04.012
20. Wang Y, Shen C, Ge J, Duan H. Regular Aspirin Use and Stomach Cancer Risk in China. *Eur J Surg Oncol* (2015) 41:801–4. doi: 10.1016/j.ejso.2015.02.006
21. Khalaf N, Yuan C, Harnada T, Cao Y, Babic A, Morales-Oyarvide V, et al. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. *Gastroenterology* (2018) 154:1380–90. doi: 10.1053/j.gastro.2017.12.001
28. Sterne JA, Hernán MA, Reeves BC, Savovíc J, Berkman ND, Viswanathan M, et al. ROBINS-I: A Tool for Assessing Risk of Bias in non-Randomised Studies of Interventions. BMJ (2016) 355:i4919. doi: 10.1136/bmj.i4919

29. Paganiini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin Use and Chronic Disease: A Cohort Study of the Elderly. BMJ (1989) 299:1247–50. doi: 10.1136/bmj.299.6710.1247

30. Schreinemachers DM, Everson RB. Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study. Epidemiology (1994) 5:138–46. doi: 10.1097/00001648-199403000-00003

31. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-Steroidal Anti-Inflammatory Drugs and Bladder Cancer Prevention. Br J Cancer (2007) 92:1364–9. doi: 10.1054/bjoc.2009.1106

32. Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, et al. Use of Analgesics and Nonsteroid Anti-Inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain. Cancer Epidemiol Biomarkers Prev (2006) 15:1696–702. doi: 10.1158/1055-9965.EPI-06-0038

33. Fortuny J, Kogevinas M, Zens MS, Schmid A, Andrew AS, Heaney J, et al. Nonsteroidal Anti-inflammatory Drug Use and Cancer Risk: A Population-Based Case Control Study. BMJ Urol Oncol (2013) 31:1689–95. doi: 10.1097/00001648-199403000-00003

34. Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS. Aspirin Use and Chronic Diseases: A Cohort Study of the Elderly. Cancer Epidemiol Biomarkers Prev (2006) 15:1696–702. doi: 10.1158/1055-9965.EPI-06-0038

35. Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, et al. Aspirin Intake and Bladder Cancer Incidence in a Prospective Study. Cancer Epidemiol Biomarkers Prev (2013) 22:2233–40. doi: 10.1158/1055-9965.EPI-13-0103

36. Shih C, Hotaling JM, Wright JL, White E. Long-Term NSAID Use and Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series. J Endourol (2017) 31:1228–35. doi: 10.1089/end.2017.0587

37. Ghali F, Moses RA, Raffn E, Hyams ES. What Factors are Associated With Unplanned Return Following Transurethral Resection of Bladder Tumor? An Analysis of a Large Single Institution’s Experience. Scand J Urol (2016) 50:370–3. doi: 10.1080/21681805.2016.1201856

38. Monroy-Flórez JJ, Villamizar-Díaz M, Torres PJ, Haddad PQ, Garcia-Closas M, Lopatovynko I, et al. Nonsteroidal Anti-Inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain. Cancer Epidemiol Biomarkers Prev (2013) 22:2233–40. doi: 10.1158/1055-9965.EPI-13-0103

39. Fan et al. Aspirin Intake and Bladder Cancer.
65. Skelin M, Javor E, Lucijanic M. Aspirin Use and the Risk of Cancer. JAMA Oncol (2019) 5:912–3. doi: 10.1001/jamaoncol.2019.0611
66. Merino-Peñas T, Shiota H, Kawato H, Sato T, Kato S. Androgen Receptor Functions in Male and Female Physiology. J Steroid Biochem Mol Biol (2008) 109:236–41. doi: 10.1016/j.jsbmb.2008.03.023
67. Li Y, Izumi K, Miyamoto H. The Role of the Androgen Receptor in the Development and Progression of Bladder Cancer. Ipn J Clin Oncol (2012) 42:569–77. doi: 10.1093/jjco/hys072
68. Sanguedolce F, Cormio L, Carrieri G, Calò B, Russo D, Menin A, et al. Role of Androgen Receptor Expression in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Histol Histopathol (2020) 35:423–32. doi: 10.14670/HH-18-189
69. Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer (2016) 2:127–37. doi: 10.3233/BLC-160052
70. Santella C, Rouette J, Brundage MD, Filion KB, Azoulay L. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Bladder Cancer: A Systematic Review of Observational Studies. Urol Oncol (2020) 38:816–25. doi: 10.1016/j.urolonc.2020.04.028
71. Bilani N, Bahmad H, Abou-Kheir W. Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. Front Pharmacol (2017) 8:145. doi: 10.3389/fphar.2017.00145
72. Garland LL, Guillen-Rodriguez J, Hsu CH, Yozwiak M, Zhang HH, Alberts D, et al. Hematopoietic Mutations Linked to Platelet Traits and the Risk of Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease in Super-Aging Society. Int J Cardiol (2020) 301:108–13. doi: 10.1016/j.ijcard.2019.09.037
73. Whitney DG, PETerson MD. The Association Between Differing Grip Strength Measures and Mortality and Cerebrovascular Event in Older Adults: National Health and Aging Trends Study. Front Physiol (2018) 9:1871. doi: 10.3389/fphys.2018.01871
74. Figgins E, Choi YH, Speechley M, Montero-Odasso M. Associations Between Potentially Modifiable and Non-Modifiable Risk Factors and Gait Speed in Middle and Older-Aged Adults: Results From the Canadian Longitudinal Study on Aging. J Gerontol A Biol Sci Med Sci (2021) glab008. doi: 10.1093/gerona/glab008
75. Czachorowski MJ, Amaral AF, Montes-Moreno S, Lloreta J, Carrato A, Tardón A, et al. Cyclooxygenase-2 Expression in Bladder Cancer and Patient Prognosis: Results From a Large Clinical Cohort and Meta-Analysis. Piló (2016) 2:e45025. doi: 10.1371/journal.pone.0045025
76. Fan B, Zhang H, Jin H, Gui Y, Wang H, Zong H, et al. Is Overexpression of Ki-67 a Prognostic Biomarker of Upper Tract Urinary Carcinoma? A Retrospective Cohort Study and Meta-Analysis. Cell Physiol Biochem (2016) 40:1613–25. doi: 10.1159/000453211
77. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kellogg GJ, McCormick DL. Differential Activity of Aspirin, Ketoprofen and Sulindac as Cancer Chemopreventive Agents in the Mouse Urinary Bladder. Carcinogenesis (1996) 17:1435–8. doi: 10.1093/carcin/17.7.1435
78. Goodman B, Gardner H. The Microbiome and Cancer. J Pathol (2018) 244:667–76. doi: 10.1002/path.5047
79. Yang Y, Misra BB, Liang L, Bi D, Weng W, Wu W, et al. Integrated Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Commensal Bacteria and Metabolites in Colorectal Cancer. Theranostics (2019) 9:4101–14. doi: 10.7150/thno.35186
80. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin (2018) 68:425–45. doi: 10.3322/caac.21494

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Fan, Mohammed, Huang, Luo, Zhang, Tao, Xu, Liu, He, Jin, Sun, Sun, Yun, Zhao, Wu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.